Company Profile

Lpath Inc (AKA: Medlyte Inc~Lpath Therapeutics Inc)
Profile last edited on: 12/1/2023      CAGE: 47LS3      UEI: G88UKSF56RY1

Business Identifier: Monoclonal antibodies for the neutralization of bioactive lipids
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4025 Sorrento Valley Boulevard
San Diego, CA 92121
   (858) 678-0800
Location: Single
Congr. District: 51
County: San Diego

Public Profile

In September 2016, Lpath and Apollo Endosurgery merged to create NASDAQ-listed medical device company focused on developing and commercializing minimally-invasive interventional treatments for obesity with Apollo owning the majority of stock. Formerly a subsidiary of Neighborhood Connections Inc and before that doing business as Medlyte Inc., Lpath Therapeutics Inc, is a biomedical company focused on the research and development of monoclonal antibodies that can target and neutralize bioactive lipids. Lipidomics, the study of lipids, is an emerging field of research that has identified dozens of bioactive lipids that contribute to disease. Once a disease-causing lipid is identified, the next step, generating a compound that neutralizes the relevant bioactive lipid, has proven difficult. Lpath has developed a platform technology, ImmuneY2, to generate monoclonal antibody drug candidates for two well-validated two bioactive lipid targets: S1P and LPA. The company is currently applying the ImmuneY2 technology to other bioactive lipid targets that are involved in important disease processes, such as inflammation, cancer, pain, asthma and sepsis.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Gary Atkinson -- CEO Chief Financial Officer

  Scott Pancoast -- President; Chief Executive Officer

  Amy L Cavalli

  William Garland -- Vice President of Research and Development

  Leigh Hsu -- Vice President of Corporate Development

  Rosalia Gerarda Matteo -- Scientist II

  Dario A Paggiarino -- Senior Vice President; Chief Development Officer

  Roger A Sabbadini -- Vice President; Chief Scientific Officer

  Jonathan Michael Wojciak -- Reseach Associate III

  Gary Woodnutt -- Senior Vice President of Research